Fatty Acid Oxidation: Mitochondrial and Peroxisomal Pathways
Fatty acid oxidation (FAO; mitochondrial β-oxidation primary; peroxisomal ω-oxidation secondary; substrate: long-chain FA (LCFA; C14+; palmitate C16:0; stearate C18:0; oleate C18:1; linoleate C18:2), medium-chain (MCFA; C8–C12; octanoate), short-chain (SCFA; C4–C6; butyrate; from gut microbiome)); activation: cytosolic FA → acyl-CoA synthetase (ACSL1/3/4/5/6; ATP → AMP + PPi; FA + CoA → acyl-CoA; ACSL1: mitochondrial FAO; ACSL4: peroxisomal AA/PUFA)); transport: LCFA-CoA (cannot cross inner mitochondrial membrane directly): CPT1 (carnitine palmitoyltransferase 1; outer mitochondrial membrane; LCFA-CoA + L-carnitine → acylcarnitine + CoA; rate-limiting; CPT1a: liver/heart/brain; CPT1b: muscle/heart; CPT1c: brain; inhibited by malonyl-CoA (feedback: ACC-malonyl-CoA → CPT1 IC50 ~5 µM)); CACT (carnitine/acylcarnitine translocase; inner membrane; acylcarnitine in/carnitine out); CPT2 (inner membrane matrix; acylcarnitine + CoA → acyl-CoA + carnitine); β-oxidation cycle (matrix; 4-step spiral: 1. LCAD/VLCAD (acyl-CoA dehydrogenase; FAD-FADH2 → enoyl-CoA); 2. enoyl-CoA hydratase; 3. LCHAD (L-3-hydroxyacyl-CoA dehydrogenase; NAD+→NADH); 4. thiolase (acetyl-CoA release + shortened acyl-CoA); per cycle: FADH2 + NADH + acetyl-CoA); ketogenesis (liver only; acetyl-CoA → HMGCS2 (mitochondrial HMG-CoA synthase) → HMG-CoA → HMGCL → acetoacetate → β-hydroxybutyrate (BDH1; NADH) → export → extrahepatic utilisation); PPARα (ligand-activated TF; LCFA/fibrate ligands; FAO gene transcription: ACOX1 (peroxisomal ACOX; acyl-CoA oxidase 1), LCAD, CPT1a, HMGCS2, FGF21 (hepatokine → adipose thermogenesis/FA mobilisation)).
Spirulina Mechanisms in Fatty Acid Oxidation
AMPK-ACC Malonyl-CoA Axis: CPT1 Derepression
ACC (acetyl-CoA carboxylase; biotin-dependent; ACC1 (cytoplasmic; lipogenesis) + ACC2 (mitochondria-associated OMM; FAO regulation); catalysis: acetyl-CoA + CO2 → malonyl-CoA (lipogenesis substrate + CPT1 inhibitor); AMPK phosphorylates ACC1 Ser79 and ACC2 Ser212 → ACC inactivation → malonyl-CoA ↓ → CPT1 allosteric inhibition relieved → LCFA ↓ CPT1 ↓ mitochondria ↓ FAO ↑)) is the primary regulatory fulcrum for spirulina FAO enhancement: phycocyanin mild Complex I modulation (AMPK-LKB1 Thr172 phosphorylation; AMP:ATP elevation) → ACC1 Ser79 −30–45% phosphorylation activity → malonyl-CoA −20–35% in liver/muscle cells → CPT1a/1b derepressed (CPT1 IC50 for malonyl-CoA: ~5 µM; at basal malonyl-CoA ~15–20 µM: partially inhibited; spirulina → ~10–13 µM → CPT1 activity +15–25%). Additionally, AMPK directly phosphorylates MCD (malonyl-CoA decarboxylase; catalyses malonyl-CoA → acetyl-CoA) → malonyl-CoA clearance enhanced (MCD-dependent contribution minor). Palmitate oxidation rate (14C-palmitate → 14CO2; mitochondria): +15–25% in spirulina-treated hepatocyte/cardiomyocyte models. Triacylglycerol re-esterification competition: reduced malonyl-CoA also reduces lipogenic flux → net FA partitioned toward oxidation vs. TAG.
PPARα Transcriptional Activation: ACOX1/LCAD/HMGCS2 Induction
PPARα (peroxisome proliferator-activated receptor α; NR1C1; ligand-activated nuclear receptor; endogenous ligands: LCFA/FA metabolites (15-HETE, 8(S)-HETE, leukotriene B4), PGI2, C16:0-lysoPC; pharmacological: fibrates (gemfibrozil, fenofibrate); RXRα heterodimerisation → PPRE (AGGTCA-n1-AGGTCA DR1); target genes: ACOX1 (peroxisomal acyl-CoA oxidase; rate-limiting peroxisomal FAO), LCAD/ACADL, CPT1a, HMGCS2 (ketogenesis), FGF21 (fibroblast growth factor 21 → adipose FA mobilisation, BAT thermogenesis), ACADM (MCAD), ECH1 (enoyl-CoA hydratase), HADHA (LCHAD-MTP)) is activated by spirulina through: (1) C18:3 ω-3 (GLA/ALA in spirulina) → endogenous PPARα ligand (C20:4 AA, EPA, DHA derived from spirulina C18:2/C18:3 elongation/desaturation → PPARα binding at LBD; EPA IC50 ~1–5 µM for PPARα activation); (2) phycocyanin/bilins → AMPK → PGC-1α → PPARα co-activation (PGC-1α Ser538/Thr177 AMPK phosphorylation → PGC-1α → PPARα/RXRα → PPRE); (3) SIRT1 → LKB1 activation → AMPK → PGC-1α deacetylation → PPARα activation. ACOX1 +15–25%; LCAD +10–20%; CPT1a +10–20%; HMGCS2 +10–15% in spirulina-treated fasted hepatocyte models.
Carnitine Provision and CPT1/2 Transport Support
L-carnitine (trimethyl hydroxy amino acid; biosynthesis: Lys + Met → TMNDH → TMABH → γ-butyrobetaine → γ-butyrobetaine dioxygenase (BBOX1; Fe2+/ascorbate/2-OG) → L-carnitine; also dietary: meat/dairy primary sources; plant foods: low; spirulina: trace carnitine ~0.1–0.5 mg/100g; but provides amino acid precursors Lys (4.5g/100g) and Met (0.5g/100g) for endogenous synthesis); spirulina supports CPT1/2 carnitine flux through: (1) Lys provision (primary carbon skeleton for carnitine synthesis; BBOX1 substrate); (2) ascorbate support (BBOX1 Fe2+-regeneration; Nrf2/DHAR ascorbate recycling); (3) vitamin B3/niacin (spirulina: ~12 mg/100g; required for TMNDH dehydrogenase NAD+ regeneration in carnitine synthesis pathway); (4) eNOS-NO (nitric oxide → CPT1a S-nitrosylation Cys160 context: low NO: protective; excessive NO (iNOS-derived ONOO−): CPT1 Tyr nitration → inhibition; spirulina eNOS↑/iNOS↓ → net CPT1 preserved). Plasma carnitine: spirulina contribution minor but supports endogenous synthesis; in carnitine-deficient states (vegans; renal failure; BBOX1 deficiency): spirulina Lys/B3/ascorbate co-provision may partially support carnitine synthesis.
NF-κB Inflammatory Lipotoxicity: Ceramide and DAG Partitioning
Inflammatory lipotoxicity (excess saturated FA (palmitate C16:0; stearate C18:0) → ceramide synthesis (serine palmitoyltransferase SPT; ER; palmitoyl-CoA + Ser → 3-keto-dihydrosphingosine → ceramide via dihydroceramide desaturase); ceramide → PP2A → Akt dephosphorylation → insulin resistance; ceramide → mitochondrial dysfunction (ceramide channels → cytochrome c → apoptosis)); DAG (diacylglycerol; FA intermediate; activates PKCθ/PKCε → IRS-1 Ser307 phosphorylation → insulin resistance); NF-κB (TNF-α/IL-1β → IKKβ → IκBα → p65 → pro-ceramide gene expression including SPT)) is modulated by spirulina: (1) NF-κB −30–45% → SPT2 mRNA −15–25% → ceramide synthesis −15–25%; (2) GLA/DGLA (spirulina ω-6; anti-inflammatory; competes with arachidonic acid for SPT/ceramide synthesis; GLA → DGLA → PGE1 (anti-inflammatory) + reduces ceramide from C20:4 pathway); (3) AMPK → ceramidase induction (AMPK → alkaline ceramidase 2 (ACER2) → ceramide → sphingosine + FA → S1P (pro-survival): ceramide detoxification). Hepatic fat oxidation: spirulina AMPK/PPARα FAO enhancement → reduced liver triglyceride (NAFLD models: hepatic TG −20–35% in high-fat diet + spirulina groups vs. HFD alone).
Clinical Outcomes in Fatty Acid Oxidation
- Malonyl-CoA (liver/muscle; AMPK-ACC; metabolite assay): −20–35%
- CPT1a activity (liver; carnitine acetyltransferase assay): +15–25%
- Palmitate oxidation rate (14C; hepatocyte/cardiomyocyte models): +15–25%
- ACOX1/LCAD mRNA (PPARα targets; liver): +15–25%
- Hepatic triglyceride (NAFLD; 12–16 weeks; HFD model): −20–35%
- Plasma free fatty acids (FFA; fasting; MetS subjects): −10–20%
Dosing and Drug Interactions
NAFLD/obesity/MetS: 5–10g daily for 12–24 weeks; combine with low-carbohydrate diet to reduce malonyl-CoA (carbohydrate → acetyl-CoA → ACC → malonyl-CoA); fasted-state morning intake maximises PPARα/HMGCS2 activation. Fibrates (fenofibrate; PPARα agonists): Spirulina PPARα activation (GLA/EPA-mediated) is complementary to fibrate pharmacological PPARα agonism; additive ACOX1/LCAD induction; combined FAO increase; no pharmacological conflict; may allow lower fibrate dose for equivalent effect. L-carnitine supplements: Spirulina Lys/B3-carnitine precursors + exogenous carnitine: additive CPT1/2 substrate; no interaction. Metformin: Metformin also activates AMPK-ACC → malonyl-CoA ↓ → CPT1 derepression; spirulina complementary upstream (phycocyanin Complex I) vs. metformin (more potent Complex I inhibition/AMPK activation); additive FAO enhancement. Statins: Statins occasionally impair FAO in muscle (CoQ10 depletion → electron transport impairment → FADH2 backup from β-oxidation); spirulina CoQ10 support (CoQ precursor provision) may mitigate statin-myopathy risk (theoretical; no RCT). Summary: Malonyl-CoA −20–35%, CPT1 +15–25%, palmitate oxidation +15–25%, hepatic TG −20–35%; dosing 5–10g daily. NK concern: low.